Scarica l'app Stockscreener
10.72
3.77%
-0.42
Dopo l'orario di chiusura:
10.56
-0.16
-1.49%
Precedente Chiudi:
$11.14
Aprire:
$11.24
Volume 24 ore:
319.85K
Relative Volume:
1.22
Capitalizzazione di mercato:
$500.74M
Reddito:
$84.82M
Utile/perdita netta:
$-21.43M
Rapporto P/E:
-12.04
EPS:
-0.89
Flusso di cassa netto:
$-27.23M
1 W Prestazione:
-27.91%
1M Prestazione:
-25.81%
6M Prestazione:
-7.59%
1 anno Prestazione:
+97.42%
Intervallo 1D:
$10.54
$11.38
Intervallo di 1 settimana:
$10.54
$14.88
Portata 52W:
$5.17
$20.90
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Nome
Y Mabs Therapeutics Inc
Settore
Industria
Telefono
212-847-9841
Indirizzo
230 PARK AVENUE, NEW YORK, NY
Confronta YMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| YMAB | 10.72 | 500.74M | 84.82M | -21.43M | -27.23M | -0.89 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Iniziato | Truist | Buy |
| 2023-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-04-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-27 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-12-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-10-31 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-03 | Ripresa | Guggenheim | Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-23 | Ripresa | Cowen | Outperform |
| 2021-03-22 | Ripresa | JP Morgan | Overweight |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-05-01 | Iniziato | Janney | Buy |
| 2020-04-29 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Iniziato | Wedbush | Outperform |
| 2019-04-01 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-10-16 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie
Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - Seeking Alpha
Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Analysts at Oppenheimer - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock - Benzinga
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics' (YMAB) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Trading (YMAB) With Integrated Risk Controls - Stock Traders Daily
YMAB FY2024 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate - Scrip
Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings - MarketBeat
Investors might be losing patience for Y-mAbs Therapeutics' (NASDAQ:YMAB) increasing losses, as stock sheds 13% over the past week - Simply Wall St
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Y-mAbs Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsY-mAbs Therapeutics, a biopharmaceutical company focusing on innovative radioimmunotherapy and antibody-based products for cancer treatment, rec - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down After Earnings Miss - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Y-mAbs Therapeutics reports Q3 2024 financials - Investing.com India
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates - MSN
Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Y-mAbs Therapeutics Inc (YMAB) Quarterly 10-Q Report - Quartzy
Y-mAbs Reports Third Quarter 2024 Financial Results - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap DownShould You Sell? - MarketBeat
Y-mAbs Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2024 - Marketscreener.com
Y mAbs Therapeutics earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada
Y-mAbs Therapeutics Inc Reports Q3 2024 Revenue of $18.5 Million - GuruFocus.com
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Q3 Revenue Falls 10%, But Secures Key Japan Deal and Patent Extension | YMAB Stock News - StockTitan
Examining the Future: Y-mAbs Therapeutics's Earnings Outlook - Benzinga
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earni - GuruFocus.com
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings - Yahoo Finance
Exclusive License Agreement Between Y-mAbs Therapeutics, Inc. and Nobelpharma Co., Ltd. for Development and Commercialization of DANYELZA(R) in Japan - Defense World
(YMAB) Trading Advice - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Y-mAbs Therapeutics Inc - GuruFocus.com
Y-mAbs enters Japan market with Nobelpharma for cancer therapy By Investing.com - Investing.com Canada
Y-mAbs enters Japan market with Nobelpharma for cancer therapy - Investing.com
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - The Manila Times
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - MSN
Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday - MarketBeat
Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday - Defense World
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal - Law360
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Objective long/short (YMAB) Report - Stock Traders Daily
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - The Manila Times
Y-Mabs Therapeutics Inc (YMAB-Q) QuotePress Release - The Globe and Mail
13,566 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by SG Americas Securities LLC - Defense World
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers (NASDAQ:YMAB) - Seeking Alpha
AQR Capital Management LLC Makes New Investment in TreeHouse Foods, Inc. (NYSE:THS) - Defense World
Cubist Systematic Strategies LLC Has $80,000 Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):